SOFIA AESCHLIMANN: Open Payments
NPI 1447255393 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,267 in 131 payments from 14 companies in 2025. Trend: 2023 $3,211 · 2024 $3,035 · 2025 $3,267
Food & beverage: $3,267
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 36 | $780 |
| Axsome Therapeutics, Inc. | 16 | $574 |
| ABBVIE INC. | 13 | $423 |
| Otsuka America Pharmaceutical, Inc. | 20 | $356 |
| Braeburn Inc. | 8 | $276 |
| Neurocrine BioSciences, Inc. | 9 | $247 |
| Vanda Pharmaceuticals Inc. | 11 | $231 |
| Alkermes, Inc. | 1 | $118 |
| E.R. Squibb & Sons, L.L.C. | 3 | $94 |
| Corium, LLC | 8 | $64 |
Products named: CAPLYTA, Auvelity, VRAYLAR, REXULTI, BRIXADI, INGREZZA, FANAPT, LYBALVI.
Industry payments across AL — which companies pay providers there.
